Canine Flu H3N8
The first licensed vaccine to protect against canine influenza, recommended for puppies and dogs that interact in public settings.
CANINE FLU H3N8 PROVIDES INFLUENZA PROTECTION FOR DOGS
Canine Influenza (H3N8) Virus (inactivated virus). Demonstrated to reduce incidence and severity of lung lesions, as well as duration of coughing and viral shedding.
Proven to significantly reduce the clinical signs, severity, and spread of canine influenza infection 1,12 Reduced the incidence and severity of coughing 1 Decreased the overall clinical signs of disease, including ocular and nasal discharge, coughing, sneezing, depression, and dyspnea 1 Reduced the days and amount of viral shedding 1 Demonstrated protection against the formation and severity of lung lesions 1 Contains killed (type A, subtype H3N8) virus combined with an adjuvant to enhance the immune response
This product has been shown to be effective for vaccination of healthy dogs 6 weeks of age or older against canine influenza virus.
Efficacy & Comparisons
NOBIVAC ® CANINE FLU H3N8 PROTECTS THE LUNGS 12
In a canine influenza virus (CIV) challenge study, vaccinated dogs exhibited significantly fewer signs of consolidation and lung damage than dogs in the control group
12 Nobivac Canine Flu H3N8 was shown to provide protection by reducing disease severity, lung lesions, and shedding
NOBIVAC ® CANINE FLU H3N8 IS HIGHLY EFFECTIVE IN REDUCING CLINICAL SIGNS OF CANINE INFLUENZA VIRUS (CIV) INFECTION 12
Shown to significantly reduce the incidence of cough
12 Reduced severity of cough
NOBIVAC ® CANINE FLU H3N8 LESSENS THE OPPORTUNITY FOR CIV TO INFECT OTHER DOGS 12
Shown to reduce the duration and degree of nasal virus shedding.
On Day 4, controls shed 500 times more viral particles than vaccinates
Mean viral shedding lasted only 2 days in vaccinates versus 5 days in controls
Vaccinates also shed less virus overall than controls
CANINE FLU H3N8 IS A SAFE CHOICE
Safety confirmed through clinical use in more than 7 million dogs 1 Well tolerated on subcutaneous administration Proven safe across a multitude of dog breeds and ages
ADMINISTRATION AND DOSAGE
Subcutaneous injection Two 1 mL doses given two to four weeks apart Annual revaccination with one dose is recommended Available in a 25 x 1 mL dose presentation
ALSO AVAILABLE IN OTHER FORMULATIONS
Professional Resources and Educational Materials
Keep your clinic and staff informed and aware of diseases and outbreaks.
In-depth information about canine vaccinations and veterinary best practices.
Tips and guidelines for your clinic to prevent and manage canine influenza.
Use these ready-to-share posts to educate pet parents and drive business to your clinic for preventative care.
1. Data on file, Merck Animal Health.
12. Deshpande MS, Jirjis FF, Tubbs A, et al. Evaluation of the efficacy of a canine influenza virus (H3N8) vaccine in dogs following experimental challenge. Vet Ther.2009;10(3):104–112.
13. Larson LJ, Henningson J, Sharp P, et al. Efficacy of the canine influenza virus H3N8 vaccine to decrease severity of clinical disease after cochallenge with canine influenza virus and Streptococcus equi subsp. zooepidemicus. Clin Vaccine Jmmunol. 2011;18(4):559- 564.
View All Nobivac References